Mild cognitive impairment (MCI) is an early stage of memory loss or other cognitive ability loss (such as language or visual/spatial perception) in individuals who maintain the ability to independently perform most activities of daily living.
About mild cognitive impairment
Mild cognitive impairment causes cognitive changes that are serious enough to be noticed by the person affected and by family members and friends but do not affect the individual’s ability to carry out everyday activities.
MCI can develop for multiple reasons, and individuals living with MCI may go on to develop dementia; others will not. For neurodegenerative diseases, MCI can be an early stage of the disease continuum including for Alzheimer's if the hallmark changes in the brain are present.
In some individuals, MCI reverts to normal cognition or remains stable. In other cases, such as when a medication causes cognitive impairment, MCI is mistakenly diagnosed. It is important that people experiencing cognitive changes seek help as soon as possible for diagnosis and possible treatment.
Learn more: Types of Dementia, What Is Alzheimer's?, Alzheimer's Causes and Risk Factors
Experts classify mild cognitive impairment based on the thinking skills affected:
- Amnestic MCI: MCI that primarily affects memory. A person may start to forget important information that he or she would previously have recalled easily, such as appointments, conversations or recent events.
- Nonamnestic MCI: MCI that affects thinking skills other than memory, including the ability to make sound decisions, judge the time or sequence of steps needed to complete a complex task, or visual perception.
Mild cognitive impairment is a clinical diagnosis representing a doctor's best professional judgment about the reason for a person's symptoms. Individuals living with MCI who have an abnormal brain positron emission tomography (PET) scan or spinal fluid test for amyloid beta protein, which is the protein in amyloid plaques (one of the two hallmarks of Alzheimer's), are considered to have a diagnosis of MCI due to Alzheimer’s disease.
The Alzheimer's Association partnered with the National Institute on Aging (NIA) to convene expert workgroups to update the diagnostic guidelines for MCI due to Alzheimer's disease, suggesting that, in some cases, MCI is an early stage of Alzheimer’s or another dementia.
The guidelines recommend finding a biomarker (a measurable biological factor, such as levels of a protein, that indicates the presence or absence of a disease) for people with MCI to learn whether they have brain changes that put them at high risk of developing Alzheimer’s and other dementias.
If it can be shown that changes in the brain, cerebrospinal fluid and/or blood are caused by physiologic processes associated with Alzheimer’s, the revised guidelines recommend a diagnosis of MCI due to Alzheimer’s disease.
A medical workup for MCI includes the following core elements:
- Thorough medical history, where the physician documents current symptoms, previous illnesses and medical conditions, and any family history of significant memory problems or dementia.
- Assessment of independent function and daily activities, which focuses on any changes from a person's usual level of function.
- Input from a family member or trusted friend to provide additional perspective on how function may have changed.
- Assessment of mental status using brief tests designed to evaluate memory, planning, judgment, ability to understand visual information and other key thinking skills.
- In-office neurological examination to assess the function of nerves and reflexes, movement, coordination, balance and senses.
- Evaluation of mood to detect depression; symptoms may include problems with memory or feeling "foggy." Depression is widespread and may be especially common in older adults.
- Laboratory tests including blood tests and imaging of the brain's structure.
If the workup doesn't create a clear clinical picture, the doctor may recommend neuropsychological testing, which involves a series of written or computerized tests to evaluate specific thinking skills.
Causes and risks
Research from clinical trials has demonstrated a significant reduction in the risk for developing mild cognitive impairment and dementia through the treatment of high blood pressure.
The causes of MCI are not yet completely understood. Experts believe that many cases — but not all — result from brain changes occurring in the very early stages of Alzheimer's or other neurodegenerative diseases that cause dementia.
The risk factors most strongly linked to MCI when the underlying cause is neurodegenerative disease and not another cause are advancing age, family history of Alzheimer's or another dementia, and conditions that raise risk for cardiovascular disease.
Learn more: Dementia Risk and Prevention
Treatment and outcomes
Aducanumab (Aduhelm™) has received accelerated approval as a treatment for Alzheimer’s disease by the U.S. Food and Drug Administration (FDA). This is the first FDA-approved therapy to address the underlying biology of Alzheimer’s disease. It is the first therapy to demonstrate that removing amyloid plaques, one of the hallmarks of Alzheimer’s, from the brain is reasonably likely to result in a reduction in clinical decline with benefits to both cognition and function in people living with the disease.
Aducanumab is indicated for the treatment of Alzheimer’s disease. The drug was studied in people living with early Alzheimer’s disease — which includes people with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease who also have evidence of a buildup of amyloid plaques in the brain. Treatment with aducanumab may be appropriate for people in the disease stage studied in the clinical trials. There is no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.
More research is needed on the biological changes associated with normal aging, MCI and Alzheimer’s and other dementias to better understand the causes of and risk factors for MCI and the prognosis for those with the condition.
Individuals who have been diagnosed with MCI should be reevaluated every six months to determine if symptoms have progressed.
Stay informed about research investigating MCI, Alzheimer’s and other dementias. Sign up for E-News today.
Learn more: Earlier Diagnosis
Special report on MCI
The 2022 edition of Alzheimer’s Association Alzheimer’s Disease Facts and Figures features a special report, More Than Normal Aging: Understanding Mild Cognitive Impairment, that examines the challenges physicians and the American public face in understanding and diagnosing MCI.
Among the facts:
- Approximately 12% to 18% of people age 60 or older are living with MCI.
- An estimated 10% to 15% of individuals living with MCI develop dementia each year.
- About one-third of people living with MCI due to Alzheimer’s disease develop dementia within five years.
- Forty-two percent of Americans say they worry about developing MCI due to Alzheimer’s disease.
- More than 80% of Americans know little or are not familiar with MCI, which can be an early stage of Alzheimer's.
See Facts and Figures to read the report and learn more about MCI.
Help is available
The Alzheimer's Association can help you learn more about MCI as well as Alzheimer’s disease and other dementias, and help you find local support services.